Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rapamune Whistleblower Suit Gets Jolt From Government Intervention

This article was originally published in The Pink Sheet Daily

Executive Summary

The Department of Justice has intervened in a qui tam suit alleging Wyeth promoted the immunosuppressant for off-label uses and offered kickbacks to providers. Settlement now seems more likely.

You may also be interested in...



Pfizer On Track To Settle Rapamune Investigation; Protonix Probe Still Unresolved

Pfizer has reached an agreement-in-principle with the Department of Justice in the Rapamune investigation and taken a charge of $491 million; Novartis settles allegations over the marketing of Elidel for $19.9 million.

No End In Sight: Pharma Companies Continue To Face Government Probes

No End In Sight: Pharma Companies Continue To Face Government Probes

Topics

Latest News
UsernamePublicRestriction

Register

PS071211

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel